{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":3,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":67,"n_cols":5,"rows_kept":67,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[10,2,10,3],[11,2,11,3],[15,2,15,3],[19,2,19,3],[19,4,19,5],[20,2,20,3],[20,4,20,5],[21,2,21,3],[22,2,22,3],[23,2,23,3],[24,2,24,3],[27,2,27,3],[28,2,28,3],[31,2,31,3],[31,4,31,5],[32,2,32,3],[32,4,32,5],[33,2,33,3],[33,4,33,5],[34,2,34,3],[35,2,35,3],[39,2,39,3],[40,2,40,3],[41,2,41,3],[42,2,42,3],[55,2,55,3],[56,2,56,3],[59,2,59,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910459498203321"]
[null,null,"Autore",null,"Mandl Jubilee Jenna"]
[null,null,"Titolo",null,"Property investment in Bulgaria [[electronic resource] ] : why invest? why not to invest? / / Jubilee Jenna Mandl"]
[null,null,"Pubbl/distr/stampa",null,"Hamburg, : Diplom.de, 2007"]
[null,null,"ISBN",null,"3-8366-0584-8"]
[null,null,"Descrizione fisica",null,"1 online resource (59 p.)"]
[null,null,"Disciplina",null,"332.63/24"]
[null,null,"Soggetti",null,"Real estate investment - Bulgaria"]
[{"$nulls":4},"Real property - Foreign ownership"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Title from cover."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Property Investment in Bulgaria - Why invest? Why not to invest?; I. Table of Contents; II. Abstract; 1. Introduction; 2. Hypothesis and Statement of Purpose; 2.1 Hypothesis; 2.2 Statement of Purpose; 3. Literature Review - Country Profile; 3.1 History; 3.2 Politics; 3.3 Economy; 3.3.1 Agriculture; 3.3.2 Industry; 3.3.3 Science, Technology, and Telecommunication; 3.4 Transport; 3.5 Demographic and Religion; 3.6 Culture; 3.7 Tourism; 4. Methodology; 4.1 Predictions and Speculations; 4.2 Data Sources - Ranking the Economic Climate in Bulgaria; 4.2.1 Credit Ranking"]
[{"$nulls":4},"4.2.2 Economist Intelligence Unit4.2.3 Global and Business Competitiveness Index; 4.2.4 Index of Economic Freedom; 4.2.5 World Economic Outlook; 4.2.6 Corruption Perceptions Index; 4.2.7 Educational Standards and Quality of Life Index; 5. Discussions + Findings; 5.1 Why to invest in Bulgaria; 5.1.1 Development; 5.2 Why not to invest in Bulgaria - Be Aware; 5.2.1 Real Estate Investment Trust; 5.3 Buy-to-let Investment Example; 6. Conclusion; 7. Appendix; 8. Endnotes and References; 8.1 Endnote; 8.2 References; Autorenprofil"]
[null,null,null,"Sommario/riassunto","HauptbeschreibungProperty is today's most popular financial investment. The traditional Stock Market offers high returns but it proves to be a highly volatile market. 50% of all members of \"\"The Times Rich List\"\" made their fortunes through property investments, proving that property in good condition with the right location will show an increase in value each year.Bulgaria is an exciting emerging market and currently offers property at prices impossible in other areas "]
[{"$nulls":4},"of the world. With prices steadily rising and predicted to continue to do so for some time, wise property inves"]
[null,"2.","Record Nr.",null,"UNISA996575456203316"]
[null,null,"Titolo",null,"2016 31st IEEE/ACM International Conference on Automated Software Engineering : 3-7 September 2016, Singapore, Singapore / / sponsored by Singapore Management University [and five others]"]
[null,null,"Pubbl/distr/stampa",null,"Piscataway, New Jersey : , : Institute of Electrical and Electronics Engineers, , 2016"]
[null,null,"Descrizione fisica",null,"1 online resource (899 pages)"]
[null,null,"Disciplina",null,"005.1"]
[null,null,"Soggetti",null,"Software engineering"]
[{"$nulls":4},"Computer-aided software engineering"]
[{"$nulls":4},"Teams in the workplace - Data processing"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Includes index."]
[null,"3.","Record Nr.",null,"UNINA9910139555703321"]
[null,null,"Autore",null,"Irving Peter"]
[null,null,"Titolo",null,"Clinical Dilemmas in Inflammatory Bowel Disease : New Challenges"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, : Wiley, 2011"]
[null,null,"ISBN",null,"1-283-24049-1"]
[{"$nulls":4},"9786613240491"]
[{"$nulls":4},"1-4443-4257-6"]
[{"$nulls":4},"1-4443-4254-1"]
[null,null,"Edizione",null,"[2nd ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (286 p.)"]
[null,null,"Disciplina",null,"616.344"]
[null,null,"Soggetti",null,"Clinical dilemmas"]
[{"$nulls":4},"Inflammatory bowel diseases"]
[{"$nulls":4},"Inflammatory Bowel Diseases"]
[{"$nulls":4},"Inflammatory bowel diseases - Decision making"]
[{"$nulls":4},"Inflammatory bowel diseases -- Decision making"]
[{"$nulls":4},"Intestinal Diseases"]
[{"$nulls":4},"Gastroenteritis"]
[{"$nulls":4},"Gastrointestinal Diseases"]
[{"$nulls":4},"Digestive System Diseases"]
[{"$nulls":4},"Disease"]
[{"$nulls":4},"Medicine"]
[{"$nulls":4},"Health & Biological Sciences"]
[{"$nulls":4},"Gastroenterology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,"Nota di contenuto",null,"Clinical Dilemmas inInflammatoryBowel Disease; Contents; Contributors; Preface; Part I: Genes and Phenotype in IBD; 1 Which will take us further in IBD-study of coding variation or epigenetics?; 2 IBD in different ethnic groups: same or different?; Part II: Bugs and IBD-Good, Bad, or Indifferent?; 3 How does the risk of infection influence management of IBD around the world?; 4 Traveling with IBD; 5 What to do about hepatitis B and hepatitis C in patients with IBD; 6 CMV in IBD-passenger or pathogen?; 7 Clostridium difficile in IBD: impact, prevention, and treatment"]
[{"$nulls":4},"8 Prebiotics and synbiotics: panacea or placebo9 Worms: light at the "]
[{"$nulls":4},"end of their burrow; 10 Do we really need to vaccinate all patients with IBD?; Part III: Investigating IBD; 11 Biomarkers in IBD: myth or marvel?; 12 Radiation exposure in IBD: how do we minimize the dangers?; 13 Surveillance colonoscopy in UC: what is the best way to do it?; Part IV: Medical Therapy; 5-ASA; 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?; 15 Do 5-ASAs prevent cancer?; 16 Why do we still use 5-ASAs in Crohn's disease?; Steroids"]
[{"$nulls":4},"17 Steroids in Crohn's disease: do the benefits outweigh the dangers?Immunomodulators; 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?; 19 Thiopurines and the sun: what should be done?; 20 Do thiopurines worsen risk and prognosis of cervical neoplasia?; 21 Optimizing use of methotrexate; 22 Which calcineurin inhibitor and when?; Biologics; 23 Are all anti-TNF agents the same?; 24 One drug or two: do patients on biologics need concurrent immunomodulation?; 25 How do we identify patients needing early aggressive therapy and what should we use?"]
[{"$nulls":4},"26 What is the role of biologics in UC?27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?; 28 Which extraintestinal manifestations of IBD respond to biologics?; 29 Use and abuse of biologics in pregnancy; 30 Is anti-TNF therapy safe to use in people with a history of malignancy?; 31 The risks of immunomodulators and biologics: what should we tell patients?; 32 When, how, and in whom should we stop biologics?; Part V: Other Treatments; 33 Avoiding drug interactions"]
[{"$nulls":4},"34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis?35 Stem cell transplantation for Crohn's: will it fulfill its promise?; 36 Complementary therapy: is there a needle in the haystack?; Part VI: Surgical Dilemmas in IBD; 37 Optimizing IBD patients for surgery and recovery; 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease?; 39 Laparoscopic or open surgery for IBD?; 40 Optimizing management of perianal Crohn's disease"]
[{"$nulls":4},"41 Does anti-TNF therapy increase the risk of complications of surgery?"]
[null,null,null,"Sommario/riassunto","The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice.  In this new edition, 75% of the \"dilemmas\" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease.  The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking"]